In October 2022, NHS England published Accelerating Genomic Medicine in the NHS, the first NHS genomics strategy. The strategy included a plan to establish ‘NHS Genomic Networks of Excellence’ as part of its commitment to provide a world-leading NHS Genomic Medicine Service (GMS) which provides cutting-edge benefits for patients in the NHS.

The NHS Genomic Networks of Excellence bring together NHS teams, researchers, charities and industry partners to help turn advances in genomics into better patient care.

The national networks focus on priority areas, including cancer, rare and inherited conditions, infectious diseases and using genetic information to guide medicine choices.

They develop evidence and practical approaches to help the NHS assess new genomic tests and technologies and introduce them into routine care. Their aim is to support faster diagnosis, more personalised treatment and improved outcomes for patients across England.

In October 2022, NHS England published Accelerating Genomic Medicine in the NHS, the first NHS genomics strategy. The strategy included a plan to establish ‘NHS Genomic Networks of Excellence’ as part of its commitment to provide a world-leading NHS Genomic Medicine Service (GMS) which provides cutting-edge benefits for patients in the NHS.

The NHS Genomic Networks of Excellence are designed to be partnerships between the NHS, academia, the third sector and industry to leverage expertise and resources from the broader genomics ecosystem, and to ensure there is a route towards rapid informing commissioning decisions.

The North West Genomic Medicine Service Alliance leads on the Pharmacogenomic and Medicines Optimisation NHS Genomic Network of Excellence, nationally across England.  We are also co-leads for the rare and inherited disease, and circulating tumour biomarker networks. 

This work is supported by the NHS England Genomics Programme through the NHS Genomic Networks of Excellence. 

For more information please click on the links shown below.

Genomic Networks of Excellence 2026-2028

Pharmacogenomics and medicines optimisation, lead by the North West Genomic Medicine Service 

Circulating tumour biomarkers, co lead by the North Thames and North West Genomic Medicine Service

Rare Disease and Functional Genomics, co led by the South West, North West, and North East & Yorkshire Genomic Medicine Service

Severe presentation of infectious disease, co lead by the South East, and Central & South Genomic Medicine Service 

Haemato-oncology, co led by the North East & Yorkshire, and Central and South Genomic Medicine Service 

CNS Tumour, co led by East and Central & South Genomic Medicine Service 

Integrated Risk Score, led by the Central & South Genomic Medicine Service 

Rapid WGS in childhood cancer, led by East Genomic Medicine Service 

Pre-natal, led by North Thames Genomic Medicine Service 

The Prenatal genomic network of excellence will bring together key leaders to drive prenatal genomic medicine services, by the delivery of increased non-invasive prenatal testing.

It will also develop evidence to expand the eligibility for fetal genomic testing, in addition to reviewing clinical pathways of care. 

This NHS Genomic Network of Excellence will work with industry sequencing providers and will link with the Great Ormond Street Hospital (GOSH) National Institute of Healthcare Research (NIHR) Biomedical Research Centre (BRC).

Following a rigorous process of expressions of interest and business case submissions, reviewed by NHS England Genomics Unit, NHS England national clinical directors, national specialty advisors, the Office for Life Sciences, Genomics England and other key stakeholders, a further five networks of excellence have been established in the following areas:

Further information is available from NHS England here: https://www.england.nhs.uk/genomics/nhs-genomic-networks-of-excellence/